Plain-English translation of NCT06793371 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called CK-4021586 to see if it can safely help people with a specific type of heart failure called HFpEF (heart failure with preserved ejection fraction). In this condition, the heart doesn't relax properly between beats, even though it still pumps normally. The study will test different doses of the medication over 12 weeks to find the right balance between safety and benefit.
Many people with HFpEF struggle with fatigue and shortness of breath, but treatment options are limited. Researchers believe this medication might help the heart relax better and improve symptoms, so they're testing it to see if it's safe and actually works.
You likely qualify if…
You likely don't qualify if…
You would take a daily pill (either the medication or a placebo) for 12 weeks. The study is split into three groups, with each group testing different doses to find which works best and is safest. You'll have regular heart ultrasounds (echocardiograms) to monitor your heart's response, and the research team will adjust your dose based on those results. You'll attend multiple clinic visits to check your health and answer questions about how you're feeling.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
United States